Achievements 2012

Looking back at 2012, Nordic Drugs launched two new products in the Nordic region, Teysuno^® and Oxycodone Lannacher. These products represent the profile of Nordic Drugs as a company very well, having a wide range of products in our portfolio.

1. Teysuno^® for advanced gastric cancer was launched in all countries as the first product in our aim to re-build an oncology product portfolio. It is a prioritized product in our speciality pharma portfolio and is actively promoted by key account managers in each country.

2. Oxycodone Lannacher is a generic version of Oxycontin and has been successfully launched in Sweden and Denmark. The product is a pure generic and is managed by our pricing specialists.

Launch of both products once again showed the importance of having a complete market access organization, including a full-scale regulatory department. Taking the new products to market was only made possible by an enormous effort by our internal regulatory team as well as the pricing and reimbursement team.

Taking a closer look at our existing products, one product stands out when it comes to growth. In 2011, we launched Metadon Nordic Drugs in Sweden and reached sales of €1.1 million already in 2012 and the product is now market leader in Sweden. Well done!

All events described above involve Rx-products only, but in terms of growth per business area we see that our OTC portfolio has had the best growth when summarizing the year. Our best selling product in 2012 was an OTC-product, Gaviscon^® with sales of €4.5 million.

Prospects for 2013

Nordic Drugs already signed agreements for two new products to be launched during 2013. Once again, these products represent the capabilities to launch various types of products, one being a pure generic (pain management) and the other one being a speciality pharma product (GI). In addition to these two products, we are in the final stage of signing two products that will fit in our OTC portfolio. Both of them with expected launch in 2013.

We have high expectations on a continued growth of Metadon Nordic Drugs as well as successful launches of the new products. Finally, we are eager to explore all the new product opportunities that will be evaluated during the year to come.